NICHOLS PLC (NICL) — Investment Research Note

Executive summary

Nichols is a UK-listed, asset-light soft drinks group built around the heritage Vimto brand, with three routes to market: UK Packaged (~52% of revenue), International Packaged (concentrated in West Africa and the Middle East, ~25%) and Out of Home (~23%). Across the 2021-2026 period the Group has recovered from the pandemic disruption to OoH, restructured that division for margin, completed an SAP ERP rollout (with the "exceptional" cost wrapper now ending), and pivoted Africa from finished-can exports to a higher-margin concentrate model — driving adjusted PBT from £11.6m (FY20) to a consensus £35.3m (FY26). The single most important point for valuation today is that the bull case (medium-term £45m PBT / 20% margin by ~FY28) is plausibly underwritten by an asset-light, net-cash balance sheet and a credible mix-shift, but headline P/E of ~15x and modest organic growth mean the upside is limited and slow-burn rather than asymmetric.

Fair value estimate

Methodology: Blended multiples — P/E on FY26 adjusted EPS plus EV/EBIT cross-check, sanity-checked against the medium-term target.

Key inputs (from FY24/H1-25 and FY26 consensus):

• FY26 consensus revenue £183.1m, adj PBT £35.3m 2026-04 AGM
• Apply ~25% tax → FY26 adj net income ~£26.5m → EPS ~72.5p on 36.5m shares
• Net cash £59.8m at end-Q1 FY26 2026-04 AGM, pension surplus £3.9m 2025 H1
• Medium-term ambition: revenue ≥£225m, PBT ≥£45m, 20% PBT margin 2024-11 CMD

Fair value range:

• Low case: 14x FY26 EPS (72.5p) + no premium for cash beyond operating need → ~1015p
• Base case: 15.5x FY26 EPS + add ~80p of surplus cash above operating need → ~1205p
• High case: discount the medium-term EPS (~92p at £45m PBT) at ~12% for 2.5 years and apply 16x → ~1400p

Stated range: 1050p – 1300p, midpoint ~1175p, implying market cap ~£385–£475m, mid ~£430m.

Current price implied by £358.4m market cap on ~36.5m shares = ~982p.

Upside to midpoint: ~+20% (range: +7% to +32%). View: modestly undervalued / fair.

Sector context

Classification confirmed: Consumer Staples / Food, Beverage and Tobacco. Nichols is a small, asset-light premium-brand player with above-peer ROCE (adj ROCE 30.4% H1 2025 2025-07) and a fortress balance sheet vs. typical leveraged staples peers. Growth is below the global beverage majors but mix is improving with the concentrate shift. Comparable peers: AG Barr (BAG.L — closest UK comp, similar mix and asset-light model), Britvic (now Carlsberg), Fevertree Drinks (FEVR.L — premium mixers, asset-light).

Investment thesis

1. Margin step-up from West Africa concentrate model. The shift from shipping finished cans to a local concentrate model is structurally lifting International gross margins (International revenue +11.1% in Q1 FY26 with Africa being the driver, and concentrate model "delivers a step change in margins") — this is the cleanest growth/profitability lever in the equity story 2026-04 AGM.
2. Fortress balance sheet with disciplined cash return. Net cash £59.8m (~17% of mcap), zero debt, pension surplus, history of paying both ordinary dividends with ~2x cover AND special dividends (£20m in 2024) when surplus accumulates 2024-07 Interims; downside protection is genuine.
3. Reasonable valuation vs. a credible medium-term plan. FY26 consensus PBT £35.3m on £358m mcap is ~13.5x P/E ex-cash; if management delivers the CMD target of £45m PBT by the medium term, this is a 10-11x business with a long-life brand and pristine balance sheet 2024-11 CMD.

Key risks

1. Middle East geopolitical / supply-chain disruption. Board explicitly flags potential volatility in supply chains and input costs from the Middle East conflict; though direct exposure is "limited" (<2% of revenue to most-tariffed corridors per prior US-tariff disclosure) and they have contractual cost cover for H1, escalation could disrupt the Vimto Ramadan trade 2026-04 AGM; 2025-04 AGM.
2. OoH consumer cyclicality and SLUSH PUPPiE / ICEE pivot. The OoH unit has already been rationalised twice in 5 years (Starslush exit, OoH strategic review). Continued UK consumer pressure or a poor cinema cycle for ICEE would erode the ~£40m OoH revenue line 2025-07 H1; 2023-07 H1.
3. Limited organic growth + execution risk on medium-term ambition. Group revenue CAGR ~1-2% over the past three years; closing a ~30% revenue gap to the £225m CMD target requires sustained international acceleration that is not yet visible in the headline number 2026-01 FY25 trading update; 2024-11 CMD.

Operating leverage

Operating leverage is moderate, not high. From the H1 2025 segmental detail, Packaged operating margin is ~29% and OoH ~16.5%, with central overheads of ~£8.8m (H1) / ~£18.6m (FY24) — i.e. central costs are ~10-11% of revenue and largely fixed 2025-07 H1; 2024-07 H1. Gross margin sits ~44%; cost of sales is dominated by raw materials, packaging and contract manufacturing (an asset-light/outsourced model) which scale roughly with volume. The concentrate-vs-finished-product mix shift in Africa is the most powerful margin lever in the model — revenue drops but unit profitability rises materially. If group revenue surprised +10-20% vs. plan, I would model adj operating profit rising perhaps 20-35% (incremental contribution above the central cost base) — meaningful but not the "multiples-of-profit" leverage this investor seeks. The model is far closer to a branded-consumer compounder than a fixed-cost platform business.

Value-trap signals

None identified that suggest structural impairment. Mild yellow flags only: (i) recurring "exceptional" ERP/business-change charges across 2021-2025 (£7.4m in FY24, £3.2m H1 2025) blur the adjusted PBT picture, although management now states the programme is complete 2026-04 AGM; 2025-07 H1; (ii) historic incentive scheme HMRC settlement (£4.3m, 2022) is a one-off but is a reminder of past governance lapses 2022-07 H1; (iii) frequent CFO turnover (Rattigan resigned 2023; Newman to interim Taylor to Hughes interim to Rothwell 2026) 2026-01 trading update; 2023-04 AGM. Family control via Relationship Agreement is well-established and disclosed, not a red flag.

Earnings vs. expectations

The pattern over 2021–2025 is mostly in-line with occasional small beats — a high-quality, low-drama earnings cadence:

• FY21: PBT guided £18.9m → reported £21-22m (modest beat post-Q3 upgrade) 2021-11 trading update
• FY23: consensus £25.2m → reported "slightly above" 2024-01 trading update
• FY24: consensus £30.1m → in line; H1 24 came in "slightly ahead" of consensus £28.8m 2025-01 trading update; 2024-07 H1
• FY25: consensus £33.1m → in line 2026-01 trading update
• FY26 to date: Q1 trading "in line" with consensus revenue £183.1m / PBT £35.3m 2026-04 AGM

Management guidance language is consistently conservative and recent quarters have reiterated rather than upgraded — no obvious sandbagging, no obvious misses.

Conviction

Conviction: 4 (high). Anchors: (i) high-quality, transparent financial disclosure with clear segmental data, (ii) net-cash balance sheet leaves valuation relatively insensitive to discount-rate assumptions, (iii) consistent guidance discipline over multiple years. Caveats: (i) the medium-term £45m PBT target embeds an acceleration that isn't yet visible in the headline (which widens the high end of the fair-value range), (ii) the AIM listing and small float mean liquidity-driven discounts are possible and not modelled.